Breaking News

Huntingdon Life Sciences and Harlan Laboratories Backed by Investors

Combined company has received a commitment of up to $125 million in minority equity financing

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Huntingdon Life Sciences (HLS) and Harlan Laboratories, soon to be called Envigo, has received a commitment of up to $125 million from group of investors in a minority equity financing that can be used to fund future growth initiatives. “We recently announced our rebranding of the company to Envigo as we complete the integration of HLS and Harlan to broaden the support we provide to life science research,” said chief executive officer, Brian Cass. “This equity investment of up to $125 million...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters